Coexisting with clonal evolution and BCR-ABL mutant in CML patients treated with second-generation tyrosine kinase inhibitors predict the discrepancy of in vitro drug sensitivity.
about
Coexisting with clonal evolution and BCR-ABL mutant in CML patients treated with second-generation tyrosine kinase inhibitors predict the discrepancy of in vitro drug sensitivity.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Coexisting with clonal evoluti ...... of in vitro drug sensitivity.
@ast
Coexisting with clonal evoluti ...... of in vitro drug sensitivity.
@en
type
label
Coexisting with clonal evoluti ...... of in vitro drug sensitivity.
@ast
Coexisting with clonal evoluti ...... of in vitro drug sensitivity.
@en
prefLabel
Coexisting with clonal evoluti ...... of in vitro drug sensitivity.
@ast
Coexisting with clonal evoluti ...... of in vitro drug sensitivity.
@en
P2093
P2860
P356
P1476
Coexisting with clonal evoluti ...... of in vitro drug sensitivity.
@en
P2093
Deok-Hwan Yang
Hyeoung-Joon Kim
Hyun Jeong Shim
Ik-Joo Chung
Jae-Sook Ahn
Je-Jung Lee
Myung Gun Shin
Sang-Hee Cho
Se Ryeon Lee
P2860
P356
10.4143/CRT.2010.42.1.37
P577
2010-03-31T00:00:00Z